Thus, our present study provides an alternative strategy to develop TH therapies for a cluster of obesity-related metabolic and vascular complications with superior efficacy and safety by releasing TH or activating TH receptors selectively in adipose tissues. Here, TH is linked to obesity due to melanocortin 4 receptor deficiency.